pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Nonprofit arbitrators under No Surprises Act earning large profits, investigation finds

Oct 19, 2026·read at STAT ↗RegulatoryNegative

A recent STAT investigation examined the role of nonprofit organizations that serve as arbitrators under the No Surprises Act. The report found that these entities are generating substantial revenue by handling disputes over unexpected medical bills.

One highlighted case is iMPROve Health, a Michigan‑based nonprofit that once faced severe financial losses and even considered a merger. Within a few years the organization turned around its finances and now reports a profit margin comparable to major technology firms.

The findings raise concerns that the law intended to protect patients is also creating lucrative opportunities for middlemen and health‑care providers, potentially affecting the overall cost structure of medical services.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing it”

read at STAT ↗
534 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.7AMICUS THERAPEUTICS, INC.Life Biosciences Inc.
topics
Oncology2AdComApprovalKRAS

related stories

  • 3d agoMerck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine successSTAT
  • 3d agoSTAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancerSTAT
  • Aug 26Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDABioPharma Dive
  • Jun 26FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesBioPharma Dive
  • May 6ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Goonclive